Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada
- PMID: 37488683
- DOI: 10.1111/add.16273
Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada
Abstract
Background and aims: Despite the significant burden of alcohol use disorder (AUD) and availability of safe and effective medications for AUD (MAUD), population-level estimates of access and engagement in AUD-related care are limited. The aims of this study were to generate a cascade of care for AUD in British Columbia (BC), Canada, and to estimate the impacts of MAUD on health outcomes.
Design: This was a retrospective population-based cohort study using linked administrative health data.
Setting: British Columbia, Canada, 2015-2019.
Participants: Using a 20% random sample of BC residents, we identified 7231 people with moderate-to-severe alcohol use disorder (PWAUD; overall prevalence = 0.7%).
Measurements: We developed a six-stage AUD cascade (from diagnosis to ≥6 months retention in MAUD) among PWAUD. We evaluated trends over time and estimated the impacts of access to MAUD on AUD-related hospitalizations, emergency department visits and death.
Findings: Between 2015 and 2019, linkage to AUD-related care decreased (from 80.4% to 46.5%). However, rates of MAUD initiation (11.4% to 24.1%) and retention for ≥1 (7.0% to 18.2%), ≥3 (1.2% to 4.3%) or ≥6 months (0.2% to 1.6%) increased significantly. In adjusted analyses, access to MAUD was associated with reduced odds of experiencing any AUD-related adverse outcomes, with longer retention in MAUD showing a trend to greater odds reduction: adjusted odds ratio (95% CI) ranging from 0.59 (0.48-0.71) for MAUD retention <1 month to 0.37 (0.21-0.67) for ≥6 months retention.
Conclusions: Access to medications for alcohol use disorder among people with moderate-to-severe alcohol use disorder in British Colombia, Canada increased between 2015 and 2019; however, initiation and retention remained low. There was a trend between longer retention in medications for alcohol use disorder and greater reductions in the odds of experiencing alcohol use disorder-related adverse outcomes.
Keywords: British Columbia; acamprosate; alcohol use disorder; cascade of care; disulfiram; medications for alcohol use disorder; naltrexone.
© 2023 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Comment in
-
Commentary on Socias et al.: It is time to be serious about AUD treatment disparities.Addiction. 2023 Nov;118(11):2139-2140. doi: 10.1111/add.16323. Epub 2023 Aug 23. Addiction. 2023. PMID: 37612825 No abstract available.
References
REFERENCES
-
- Collaborators G. B. D. R. F. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1223-1249.
-
- Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019) results Seattle, United States: Institute for Health Metrics and Evaluation (IHME); 2020.
-
- Statistics Canada. Table 13-10-0096-01 Health characteristics, annual estimates Statistics Canada; 2021.
-
- Canadian Institute for Health Information. Hospitalizations entirely caused by alcohol [indicator]; 2019.
-
- Statistics Canada. Provisional death counts and excess mortality, January 2020 to October 2022: The Daily, January 12, 2023.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
